FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3210314254> ?p ?o ?g. }

• W3210314254 endingPage "28641" @default.
• W3210314254 startingPage "28630" @default.
• W3210314254 abstract "Naringin (NAR), a naturally occurring essential flavonoid, present in grapefruit and Chinese herbal medicines, creates great interest in researchers due to its diverse biological and pharmacological activities. However, further development of NAR is hindered due to its poor water solubility and dissolution rates in GIT. To address these limitations, in this study, we report polymeric nanoparticles (NPs) of NAR (NAR-PLGA-NPs) for enhancing the oral NAR efficiency, with a biodegradable polymer (PLGA) to improve its absorption and bioavailability. NAR-PLGA-NPs were fabricated by a modified solvent emulsification-evaporation technique. Physicochemical properties were evaluated by SEM, particle size distribution, entrapment efficiency, Fourier transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), and differential scanning calorimetry (DSC). In vitro drug release and ex vivo permeation studies were carried out in phosphate buffer (pH 6.8) for 24 h. Furthermore, in vivo anti-arthritic studies were performed on a mouse model, and the results were compared with free NAR. The modulation of inflammatory mediators was also evidently supported by docking studies. Optimized nanoformulation FN4 (NAR-PLGA-NPs) prepared with acetone-ethanol (2:1) as a solvent system in a combination of stabilizers, i.e., poloxamer-188 and sodium deoxylate (1:1), along with 2% PVA solution, was prepared. From size characterization studies, it was observed that nanoformulations possessed a low particle size (179.7 ± 2.05 nm), a low polydispersity index (0.206 ± 0.001), and a negative zeta potential (-9.18 ± 0.78 mV) with a maximum entrapment efficiency (74 ± 3.61%). The drug release followed a Korsmeyer-Peppas release kinetic model (anomalous non-Fickian diffusion), providing greater NAR release after lyophilization (82.11 ± 3.65%) drug release in pH 6.8 phosphate buffer for 24 h. Ex vivo permeation analysis through an isolated goat intestinal membrane revealed 80.02 ± 3.69% drug release in 24 h. Encapsulation of a drug into PLGA is well described by the results of FTIR, DSC, and XRD. Finally, the therapeutic efficacy of optimized FN4 (NAR-PLGA-NPs) and its possible application on RA were further confirmed in a Freund's complete adjuvant-induced rat arthritic model as against free NAR at a dose of 20 mg/kg body wt. Our findings demonstrate that sustained action of NAR from optimized FN4 NPs with a rate-controlling polymeric carrier system exhibited prolonged circulation time and reduced arthritic inflammation, hence indicating the possibility as a novel strategy to secure the unpropitious biological interactions of hydrophobic NAR in a gastric environment." @default.
• W3210314254 created "2021-11-08" @default.
• W3210314254 creator A5000330321 @default.
• W3210314254 creator A5005030868 @default.
• W3210314254 creator A5030894364 @default.
• W3210314254 creator A5034760600 @default.
• W3210314254 creator A5081764697 @default.
• W3210314254 date "2021-10-22" @default.
• W3210314254 modified "2023-10-18" @default.
• W3210314254 title "Naringin as Sustained Delivery Nanoparticles Ameliorates the Anti-inflammatory Activity in a Freund’s Complete Adjuvant-Induced Arthritis Model" @default.
• W3210314254 cites W1517095527 @default.
• W3210314254 cites W1854307882 @default.
• W3210314254 cites W1983001611 @default.
• W3210314254 cites W1988652094 @default.
• W3210314254 cites W1991933724 @default.
• W3210314254 cites W2006516099 @default.
• W3210314254 cites W2008376262 @default.
• W3210314254 cites W2011317507 @default.
• W3210314254 cites W2013754028 @default.
• W3210314254 cites W2018898714 @default.
• W3210314254 cites W2020398834 @default.
• W3210314254 cites W2027367649 @default.
• W3210314254 cites W2028629350 @default.
• W3210314254 cites W2030266308 @default.
• W3210314254 cites W2043782706 @default.
• W3210314254 cites W2044325823 @default.
• W3210314254 cites W2059591955 @default.
• W3210314254 cites W2062753270 @default.
• W3210314254 cites W2066685510 @default.
• W3210314254 cites W2078639851 @default.
• W3210314254 cites W2079502732 @default.
• W3210314254 cites W2086492789 @default.
• W3210314254 cites W2087363756 @default.
• W3210314254 cites W2088998266 @default.
• W3210314254 cites W2104417536 @default.
• W3210314254 cites W2119023371 @default.
• W3210314254 cites W2119310721 @default.
• W3210314254 cites W2120060289 @default.
• W3210314254 cites W2124199887 @default.
• W3210314254 cites W2127983008 @default.
• W3210314254 cites W2148628183 @default.
• W3210314254 cites W2155142470 @default.
• W3210314254 cites W2166285205 @default.
• W3210314254 cites W2216824414 @default.
• W3210314254 cites W2285221808 @default.
• W3210314254 cites W2295264984 @default.
• W3210314254 cites W2367982160 @default.
• W3210314254 cites W2514937930 @default.
• W3210314254 cites W2741507210 @default.
• W3210314254 cites W2772166841 @default.
• W3210314254 cites W2792731182 @default.
• W3210314254 cites W2884459466 @default.
• W3210314254 cites W2935732657 @default.
• W3210314254 cites W2953780526 @default.
• W3210314254 cites W2955244649 @default.
• W3210314254 cites W2993641112 @default.
• W3210314254 cites W3012381788 @default.
• W3210314254 cites W3013505907 @default.
• W3210314254 cites W3096473443 @default.
• W3210314254 cites W563320767 @default.
• W3210314254 cites W639108217 @default.
• W3210314254 doi "https://doi.org/10.1021/acsomega.1c03066" @default.
• W3210314254 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8567265" @default.
• W3210314254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34746558" @default.
• W3210314254 hasPublicationYear "2021" @default.
• W3210314254 type Work @default.
• W3210314254 sameAs 3210314254 @default.
• W3210314254 citedByCount "11" @default.
• W3210314254 countsByYear W32103142542022 @default.
• W3210314254 countsByYear W32103142542023 @default.
• W3210314254 crossrefType "journal-article" @default.
• W3210314254 hasAuthorship W3210314254A5000330321 @default.
• W3210314254 hasAuthorship W3210314254A5005030868 @default.
• W3210314254 hasAuthorship W3210314254A5030894364 @default.
• W3210314254 hasAuthorship W3210314254A5034760600 @default.
• W3210314254 hasAuthorship W3210314254A5081764697 @default.
• W3210314254 hasBestOaLocation W32103142543 @default.
• W3210314254 hasConcept C101335993 @default.
• W3210314254 hasConcept C11432220 @default.
• W3210314254 hasConcept C121332964 @default.
• W3210314254 hasConcept C127413603 @default.
• W3210314254 hasConcept C13965031 @default.
• W3210314254 hasConcept C147789679 @default.
• W3210314254 hasConcept C155672457 @default.
• W3210314254 hasConcept C15920480 @default.
• W3210314254 hasConcept C160892712 @default.
• W3210314254 hasConcept C171250308 @default.
• W3210314254 hasConcept C178790620 @default.
• W3210314254 hasConcept C181389837 @default.
• W3210314254 hasConcept C185592680 @default.
• W3210314254 hasConcept C187530423 @default.
• W3210314254 hasConcept C192562407 @default.
• W3210314254 hasConcept C2777335409 @default.
• W3210314254 hasConcept C2780165375 @default.
• W3210314254 hasConcept C39519442 @default.
• W3210314254 hasConcept C42360764 @default.
• W3210314254 hasConcept C43617362 @default.
• W3210314254 hasConcept C521977710 @default.

• next